PROCEPT BioRobotics reported second quarter 2026 financial results with total revenue of $94.5 million, a 19% increase year-over-year. U.S. procedures exceeded 13,100, up approximately 21%, and the company delivered 65 HYDROS systems in the U.S., including 14 replacements, at an average selling price of roughly $495,000 per new system. Gross margin improved to 66% from 65% in the prior year period, aided by a $2.9 million tariff refund and increased pricing. Operating expenses rose to $89.8 million compared to $73.9 million previously, driven by commercial investments and clinical trial costs for the WATER IV study. The company reported a net loss of $26.9 million versus a $19.6 million loss in the prior year period. Full-year 2026 revenue guidance remains unchanged at $390 million to $410 million, while adjusted EBITDA loss expectations were widened to $35 million–$30 million from previous estimates. PROCEPT BioRobotics operates in the surgical robotics industry, developing AI-powered robotic systems and Aquablation therapy for treating benign prostatic hyperplasia.